- Home
- RMCO vs EDSA Comparison
RMCO vs EDSA Comparison
Compare RMCO & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMCO | EDSA |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.7M | 12.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RMCO | EDSA |
|---|---|---|
| Price | $2.55 | $1.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 69.0K | 32.5K |
| Earning Date | 11-13-2025 | 12-12-2025 |
| Dividend Yield | ★ 0.40% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,798,352.00 | N/A |
| Revenue This Year | $531.90 | N/A |
| Revenue Next Year | $200.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 445.90 | N/A |
| 52 Week Low | $0.91 | $1.43 |
| 52 Week High | $4.76 | $4.49 |
Technical Indicators
Market Signals| Indicator | RMCO | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 52.08 | 27.59 |
| Support Level | $2.30 | $1.43 |
| Resistance Level | $2.54 | $1.50 |
| Average True Range (ATR) | 0.19 | 0.08 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 93.18 | 0.00 |
Price Performance
Historical ComparisonAbout RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.